Shares of Biogen Idec, Celgene, Gilead Sciences, and Lexicon Pharmaceuticals recovered from last week's selloff.» Read More
Amgen Inc. rose$. 10 or. 1 percent, to $118.92. Biogen Idec fell $4.31 or 1.5 percent, to $289.88. Celgene Corp. fell $1.32 or. 9 percent, to $137.84.
*Eli Lilly ordered to pay $3 bln in damages in Actos case. *Alcoa earnings due after the close.
Despite the recent meltdown in biotech, there are still areas of opportunity within the sector, Citi's Yaron Werber says.
Amgen Inc. fell$. 29 or. 2 percent, to $118.82. Biogen Idec rose $5.92 or 2.1 percent, to $294.19. Celgene Corp. rose $1.78 or 1.3 percent, to $139.16.
Amgen Inc. fell$. 47 or. 4 percent, to $118.64. Biogen Idec rose $4.41 or 1.5 percent, to $292.68. Celgene Corp. rose$. 89 or. 6 percent, to $138.27.
*E* Trade and Netflix weigh on S&P 500 and Nasdaq. NEW YORK, April 4- Momentum shares like Netflix and TripAdvisor sold off sharply for a second straight day on Friday, giving the Nasdaq its worst day since February and leaving investors anxious about how much further they may fall.
*E* Trade and Netflix weigh on S&P 500 and Nasdaq. NEW YORK, April 4- U.S. stocks fell sharply on Friday as momentum shares like Netflix and TripAdvisor sold off for a second straight session, putting the Nasdaq on track for its second-worst day of the year.
*E* Trade and Netflix weigh on S&P 500 and Nasdaq. NEW YORK, April 4- The Nasdaq tumbled more than 2 percent on Friday as momentum stocks like Netflix and TripAdvisor sold off for a second straight session.
*E* Trade and Netflix weigh on the S&P 500 and the Nasdaq. NEW YORK, April 4- The Nasdaq tumbled more than 2 percent on Friday, led by another selloff in momentum stocks like Netflix and TripAdvisor, as investors ignored relatively strong March jobs data. Biogen Idec Inc fell 3.6 percent to $291.
*Mylan up on report of Meda AB buy. *Boeing considers Mercury Systems acquisition. Biogen Idec Inc fell 4.3 percent to $288.98.
The knock-on effects from the debate over 'rigged' markets may push high-speed trading firm Virtu to postpone its IPO.
These three stocks have pulled back to crucial support levels, Bespoke's Paul Hickey says.
Price action has led Jim Cramer to question whether 3 powerful themes have started to sputter out.
*S&P 500 rises in Q1 for its fifth straight quarterly gain. NEW YORK, March 31- U.S. stocks rose on Monday, with the S&P 500 ending both March and the first quarter of 2014 with moderate gains, after Federal Reserve Chair Janet Yellen relieved concerns about a rate hike coming earlier than expected.
Stocks wrapped up the session on a high note, with the Dow logging triple-digit gains, after Federal Reserve Chair Janet Yellen said there's still room for the central bank to help the economy. But major index ended relatively flat for the first quarter.
*S&P on track for fifth straight quarterly advance. NEW YORK, March 31- U.S. stocks rose on Monday, with the S&P 500 on track to end the first quarter of 2014 with slight gains, after Federal Reserve Chair Janet Yellen calmed concerns about a rate hike coming earlier than expected. Micron Tech climbed 7.2 percent to $23.48 while Oracle Corp added 3.6 percent to $40.98.
Take a look at some of Monday's midday movers:
March 28- Biogen Idec Inc has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration said on Friday. It affects about 4,000 people in the United States and 25,000 worldwide.
*Wall Street pares gains after late biotech selloff. NEW YORK, March 28- Global equity markets ended higher on Friday but U.S. stocks sharply pared gains after a late selloff in biotechnology shares, while euro zone government bond yields fell on renewed bets the European Central Bank will ease policy next week.
*Momentum stocks still in focus; Netflix falls. NEW YORK, March 28- U.S. stocks ended up on Friday but off their session highs as a late afternoon selloff in the biotechnology sector weighed on the overall market. The Nasdaq Composite Index fell nearly 3 percent for the week, marking its worst week since October 2012.